Shots: Bain Capital and Cinven to acquire Lonza’s specialty ingredients business and operations for an enterprise value of $4.7B. The transaction is expected to close in H2’21 The divestiture will […]readmore
Tags : business
Shots: Agios to receive ~$1.8B upfront in cash & ~$200M as regulatory milestones for Vorasidenib along with 5% royalties on sales of Tibsovo in the US from transaction close through […]readmore
Shots: Boston Scientific signs an agreement with Stark International and SERB SAS to sell its BTG specialty pharma business for $800M in cash. The transaction is expected to close in […]readmore
Shots: STADA to acquire GSK’s 15 well-established consumer healthcare brands including Venoruton, for venous treatment, Coldrex cold remedy, Cetebe vitamin C supplements, Mebucaine sore throat range and Tavegyl allergy brand […]readmore
Shots: Zentiva acquires Alvogen’s CEE market consisting of 200+ generics and OTC therapies across multiple therapeutics areas which include brands like Lactacyd, Persen, EuBiotic. The transaction is expected to be […]readmore
Shots: Elanco acquires Bayer’s animal health business in cash & stock transaction, making a total deal value $7.6B. Bayer to get $5.32B cash as up front and $2.28B/~68M as Elanco’s […]readmore
Shots: Pfizer’s is expected to spin-off Upjohn and combine with Mylan in all-stock Reverse Morris Trust transaction, with each Mylan share to be converted into one share of the new […]readmore
Shots: Novartis plans spin-off of its eye care business with an expected 100% spin-off on Apr 9, 2019 and has secured debt financing of $3.5B through banks Novartis stockholder to […]readmore
Shots: Perrigo’s separated business helps it to lead the main focus on consumer business, which includes generic medicines including topical creams, foams, mousses, gels, liquids and inhalable products […]readmore